
Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer
Treatment-emergent ocular events (TEOEs) in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer treated with mirvetuximab soravtansine (Elahere; AbbVie) during the phase 3 MIRASOL (NCT04209855) trial were not …